Dosing will be a key success factor in repurposing antivirals for COVID-19
| Errataetall: |
CommentIn: Br J Clin Pharmacol. 2021 Jan;87(1):212-213. - PMID 32384171 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 87(2021), 9 vom: 21. Sept., Seite 3451-3454 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Patrick F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 06.09.2021 Date Revised 07.12.2022 published: Print-Electronic CommentIn: Br J Clin Pharmacol. 2021 Jan;87(1):212-213. - PMID 32384171 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.14314 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308889142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308889142 | ||
| 003 | DE-627 | ||
| 005 | 20231225132717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14314 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308889142 | ||
| 035 | |a (NLM)32304110 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Patrick F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dosing will be a key success factor in repurposing antivirals for COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Clin Pharmacol. 2021 Jan;87(1):212-213. - PMID 32384171 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Dodds, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bentley, Darren |e verfasserin |4 aut | |
| 700 | 1 | |a Yeo, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Craig |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 87(2021), 9 vom: 21. Sept., Seite 3451-3454 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g number:9 |g day:21 |g month:09 |g pages:3451-3454 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14314 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2021 |e 9 |b 21 |c 09 |h 3451-3454 | ||